Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACE + Methylcantharidimide for Large Unresectable HCC
NCT03996681Phase 4Unknown
- Sponsor
- Affiliated Suzhou Hospital of Nanjing Medical University
- Start
- Jul 2019
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of methylcantharidimide in hepatocellular carcinoma (HCC), sponsored by Affiliated Suzhou Hospital of Nanjing Medical University. Primary endpoint: Disease Control Rate at 18 months. Status: unknown.
02
Drugs
methylcantharidimide
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03996681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03996681.